Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110

Leukemia. 2022 Jul;36(7):1935-1938. doi: 10.1038/s41375-022-01600-6. Epub 2022 May 18.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunoglobulin Heavy Chains
  • Immunoglobulin Variable Region
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Treatment Outcome

Substances

  • Immunoglobulin Heavy Chains
  • Immunoglobulin Variable Region